In short
Mavacamten is being studied in clinical trials for different types of hypertrophic cardiomyopathy, including obstructive and non-obstructive forms. These trials look at whether it can improve symptoms, exercise ability, heart structure, and long-term safety in adults and adolescents.
Key points
- Mavacamten is being studied in clinical trials for hypertrophic cardiomyopathy, including obstructive and non-obstructive forms. The trials include adolescents and adults, and one long-term study enrolled adults who had already taken part in earlier studies. Most of the studies are Phase 3 trials, which means they are later-stage studies that test how well the treatment works and how safe it is. The main outcomes include symptom scores, exercise capacity, blockage in blood flow from the heart, and heart structure on imaging. One long-term study also tracks serious heart events and other safety measures over time. Overall, the trials focus on whether Mavacamten can improve heart-related symptoms and heart measurements in people with this condition.
Trial overview
The clinical trials in this data study Mavacamten in people with hypertrophic cardiomyopathy, which is a condition where the heart muscle is thicker than normal. The trials look at both obstructive and non-obstructive forms of the disease, and they include adolescents and adults. Most of the studies are later-stage trials, including Phase 3 research, and one study is listed as low intervention.
Who is being studied
One Phase 3 study is in adolescent participants with symptomatic obstructive hypertrophic cardiomyopathy, and it plans to enroll 40 people. Another Phase 3 study is in adults with non-obstructive hypertrophic cardiomyopathy and enrolled 478 participants. A separate long-term study included adults who had already completed earlier mavacamten trials, MAVERICK-HCM or EXPLORER-HCM.
These studies are designed for people with different forms of the same heart condition, so the target group changes from trial to trial. This helps researchers see whether the study treatment works in specific patient groups rather than in one large mixed group.
What the trials measure
The adolescent obstructive HCM study measures the change from baseline in Valsalva LVOT gradient at Week 28. This is a test of how much blood flow is blocked as blood leaves the heart, and the Valsalva maneuver is a way to make that blockage easier to measure.
The adult non-obstructive HCM study measures change from baseline in KCCQ CSS and pVO2 at Week 48. KCCQ CSS is a patient questionnaire score that reflects symptoms and physical limits, while pVO2 is a measure of exercise capacity, or how well the body uses oxygen during exercise.
The imaging study looks at whether Mavacamten reduces heart wall thickness and upper chamber size on cardiac magnetic resonance at Week 48. This means researchers are checking heart structure with a detailed scan, not only symptoms.
The long-term extension study focuses on safety, heart events, and changes in heart structure over time. It measures major adverse cardiac events, hospitalizations, heart failure events, abnormal heart rhythms, and treatment-emergent side effects and lab changes.
Study design and phases
Three of the studies are Phase 3 trials, which are later-stage studies that help show whether a treatment works in a larger group of people. The imaging study is listed as low intervention, meaning it is focused on observation and follow-up with limited added study procedures.
Several studies compare Mavacamten with placebo, which is a look-alike treatment that does not contain the study drug. This design helps researchers judge whether changes are linked to the study treatment rather than to chance or time alone.
Key trial summaries
- 2023-505650-17-00: A Phase 3 study in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The main goal is to see whether Mavacamten changes the Valsalva LVOT gradient by Week 28.
- NCT05582395: A completed Phase 3 randomized, double-blind, placebo-controlled study in adults with non-obstructive hypertrophic cardiomyopathy. It studied health status and exercise capacity over 48 weeks.
- 2022-502316-36-00: A completed low-intervention study in symptomatic obstructive hypertrophic cardiomyopathy. It examined heart wall thickness and upper chamber size on cardiac magnetic resonance at Week 48.
- NCT03723655: A completed Phase 3 long-term extension study in adults with hypertrophic cardiomyopathy who had finished earlier trials. It tracked safety, serious heart events, and changes in heart structure.
What patients should know
These trials are not all looking at the same question, even though they all study Mavacamten. Some focus on symptom relief, some on exercise ability, some on heart imaging, and some on long-term safety.
The trial data show that researchers are trying to learn whether Mavacamten can help different age groups and different forms of hypertrophic cardiomyopathy. They are also checking whether the treatment changes heart structure and whether it remains safe during longer follow-up.